PHC Group’s
Response to



Throughout the COVID-19 pandemic, PHC Group companies worked to support the safety and health of all our stakeholders, internally and externally, including healthcare professionals, researchers, patients, and our employees around the world. From vaccine storage to remote medical care to PCR testing, PHC Group companies provided essential products and services to enable our customers to better care for their patients during this crisis.

Providing Precision Healthcare Solutions to Healthcare Providers and Institutions


Equipment for Vaccine Development and Preservation

The Biomedical Division of PHC Corporation is a global leader in life sciences equipment for research, providing the PHCbi brand of innovative equipment and services for scientific research by medical institutions, universities and pharmaceutical companies. During the COVID-19 pandemic, we supported healthcare professionals and researchers by offering high-quality ultra-low temperature freezers for storing COVID-19 vaccines and preserving patient specimens. Our customers also relied on PHCbi pharmaceutical refrigerators and CO2 incubators for developing COVID-19 medicines and vaccines.

Solutions for COVID-19 vaccine storage
PHCbi products and services

Healthcare IT Products and Services for Remote Care

During the COVID-19 pandemic, demand for online outpatient care and medical instructions increased as healthcare professionals and patients sought to reduce the risk of exposure during healthcare visits. The healthcare IT business of PHC Corporation (now WEMEX) responded to this demand in Japan by providing user-friendly services from telemedicine systems to smartphone app technology.


PCR Testing Services

LSI Medience Corporation provides medical and analytical support services across Japan and is one of the leading providers of clinical testing services. The company began providing COVID-19 PCR testing services in February 2020, at the very beginning of the global pandemic, and expanded testing equipment during the crisis to respond to rapidly increasing order requests.
Starting in December 2020, LSI Medience expanded this offering with PCR testing capable of simultaneously detecting SARS-CoV-2 and influenza nucleic acid, to test for combined infections of flu and COVID-19.

Share this page

Twitter Facebook LinkedIn